CD274 and lung cancer: Inhibitors of PD1 (such as nivolumab and pembrolizumab) and PD-L1 (such as atezolizumab) opened new possibilities for patients with advanced lung cancer, by reactivating the body’s own immune system which recognizes and destroys cancer cells31.